Drugs / Salanersen
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05575011 | Oct 2022 → Nov 2031 expected | spinal muscular atrophy | Biogen | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07444450 | Sep 2026 → Jul 2029 expected | spinal muscular atrophy | Biogen | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07221669 | Apr 2026 → Nov 2028 expected | spinal muscular atrophy | Biogen | Recruiting | No outcome recorded |
| Phase 3 | NCT07444476 | Apr 2026 → Jun 2028 expected | spinal muscular atrophy | Biogen | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Salanersen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07444450 ↗ |
| Known as | BIIB115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05575011 ↗ |
| Action | Activate | “Salanersen works by helping the SMN2 gene to make more SMN protein.” NCT07221669 ↗ |
| Route | Intrathecal | “BIIB115 administered via intrathecal (IT) bolus injection” NCT05575011 ↗ |
| Target | SMN2 | “Salanersen works by helping the SMN2 gene to make more SMN protein.” NCT07221669 ↗ |